Teplizumab, a new drug, could delay the need for insulin for patients with type 1 diabetes by up to 3 years.
Călin Nicolescu
Health
Foto Pixabay
Always see our news on Google
Teplizumab, a drug already approved in the US, is being tested in the UK to slow the progression of type 1 diabetes by training the immune system to protect pancreatic cells. Hannah Robinson, the first British adult to receive the treatment, hopes it will delay the need for insulin. Experts believe the treatment represents a major change in diabetes management, with the potential to alter the immune process and help high-risk people avoid insulin therapy.
Sources
Un medicament "revoluţionar" ar putea încetini evoluţia diabetului de tip 1. Poate întârzia nevoia de insulină cu 3 ani
Devon mother treated with game-changing diabetes drug
Mother of two becomes the first UK patient to receive ‘groundbreaking’ new diabetes drug
Un medicament „revoluționar”, o nouă speranță pentru diabetul de tip 1. Ce așteptări au medicii
Latest News
15:15
Three suspects allegedly surveilled the Carfil factory before the fire
15:14
Over 36,000 students will receive social scholarships worth 925 lei in the 2026–2027 academic year
15:05
Bucharest police are investigating eight drivers and two STB security guards for allegedly stealing fuel from buses
14:59
Senators limit cars provided under loan-for-use agreements to one per Uber and Bolt operator
14:57
Nicuşor Dan and Luca Niculescu send messages of solidarity to Spain after the railway accident that resulted in at least 30 deaths
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
_Diaspora.webp)
